Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients: A placebo-controlled study

Biological Psychiatry

Volumn 45, Issue 12, 1999, Pages 1606-1611

  Monteleone, Palmiero ^a   Tortorella, Alfonso ^a   Borriello, Renata ^a   Cassandro, Paola ^a   Maj, Mario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

D fenfluramine; Drug resistance; Prolactin; Schizophrenia; Serotonin

Indexed keywords

ALPRAZOLAM; BIPERIDEN; BROMAZEPAM; CHLORPROMAZINE; CLOTIAPINE; DEXFENFLURAMINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; ORPHENADRINE; PROLACTIN;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NEUROMODULATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ADOLESCENT; ADULT; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FENFLURAMINE; HUMANS; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; PROLACTIN; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS;

EID: 0033564434     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00270-4     Document Type: Article

References (34)

1. Abel K.M., O'Keane V., Murray R.M., Cleare A.J. Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression. Psychoneuroendocrinology. 22:1997;539-548.
2. Abel K.M., O'Keane V., Murray R.M. Enhancement of the prolactin response to D-fenfluramine in drug-naive schizophrenic patients. Br J Psychiatry. 168:1996;57-60.
3. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS). 1984;The University of Iowa, Iowa City.
4. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS). 1983;The University of Iowa, Iowa City.
5. Andreasen N.C., Endicott J., Spitzer R.L., Winokur G. The family history method using diagnostic criteria Reliability and validity . Arch Gen Psychiatry. 34:1977;1229-1235.
6. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G (1978): A Comprehensive Psychopathological Rating Scale. Acta Psychiat Scand (suppl) 271:63-69.
7. Banki C.M., Vojnik M., Arato M., Papp Z., Kovaks Z. Dexamethasone suppression and multiple hormonal responses (TSH, prolactin and growth hormone) to TRH in some psychiatric disorders. Eur Arch Psychiatr Neurol Sci. 235:1985;32-37.
8. Bleich A., Brown S.-L., van Praag H.M. A serotonergic theory of schizophrenia. Brown S.-L., van Praag H.M. The Role of Serotonin in Psychiatric Disorders. 1991;183-214 Bruner/Mazel, New York.
9. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455.
10. Coccaro E.F., Kavoussi R.J., Cooper T.B., Hauger R.L. Hormonal responses to D- and D,l-fenfluramine in healthy human subjects. Neuropsychopharmacology. 15:1996;595-607.
11. Cowen P.J., Gadhvi H., Gosden B., Kolakowska T. Responses of prolactin and growth hormone to L-tryptophan infusion effects in normal subjects and schizophrenic patients receiving neuroleptics . Psychopharmacology. 86:1985;164-169.
12. Dinan T.G. Glucocorticoids and the genesis of depressive illness. Brit J Psychiatry. 164:1994;365-372.
13. Ferrier I.N., Johnstone E.C., Crow T.J., Rincon-Rodriguez I. Anterior pituitary hormone secretion in chronic schizophrenics. Arch Gen Psychiatry. 40:1983;755-761.
14. Garattini S., Mennini T., Samanin R. From fenfluramine racemate to D-fenfluramine Specificity and potency of the effects on the serotonergic system and food intake . Ann NY Acad Sci. 199:1987;156-166.
15. Gil-Ad I., Dickerman Z., Amdursky S., Laron Z. Diurnal rhythm of plasma beta-endorphin, cortisol and growth hormone in schizophrenics as compared to control subjects. Psychopharmacology. 88:1986;496-499.
16. Gorad D.A., Taylor T.M., Medbak S.H., Perry L.A., Libby G.W., Farthing M.J.G. Plasma prolactin, adrenocorticotrophic hormone and cortisol after administration of D-fenfluramine or placebo to healthy subjects. Int Clin Psychopharmacol. 8:1993;123-128.
17. Hoshino Y., Kaneko M., Kumashiro H., Tachibana R. Endocrinological function in schizophrenic patients under haloperidol treatment Plasma PRL, HGH and 5HT levels after L-5HTP loading . Folia Psychiatr Neurol Japan. 39:1985;123-143.
18. Invernizzi R., Berettera G., Garattini S., Samanin R. D- and L-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. Eur J Pharmacol. 120:1986;9-15.
19. Iqbal N., Asnis G.M., Wetzler S., Kahn R.S., Kay S.R., van Praag H.M. The MCPP challenge test in schizophrenia hormonal and behavioral responses . Biol Psychiatry. 30:1991;770-778.
20. Iqbal N., van Praag H.M. The role of serotonin in schizophrenia. Eur Neuropsychopharmacol. 1995;S:11-S:23.
21. Kahn R.S., Davidson M., Siever L., Gabriel S., Apter S., Davis K.L. Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry. 150:1993;1337-1342.
22. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic A double-blind comparison with chlorpromazine . Arch Gen Psychiatry. 45:1988;789-796.
23. Kordon C., Drouva S.V., Martinez de la Escalera G., Weiner R.I. Role of classic and peptide neuromediators in the neuroendocrine regulation of luteinizing hormone and prolactin. Knobil E., Neill J.D. The physiology of reproduction. 1994;1621-1681 Raven Press, New York.
24. Lerer P., Ran A., Blacker M., et al. Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction. Schizophrenia Res. 1:1988;405-410.
25. Maes M., Meltzer H.Y. Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers. Psychiatry Res. 64:1996;147-159.
26. Masellis M., Basile V., Meltzer H.Y., et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 19:1998;123-132.
27. McBride P.A., Tierney H., DeMeo M., Chen J.-S., Mann J.J. Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol Psychiatry. 27:1990;1143-1155.
28. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine The dopamine-serotonin hypothesis of schizophrenia . Psychopharmacology. 112:1989;S95-S104.
29. Monteleone P., Maj M., Fusco M., Kemali D., Reiter R.J. Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophrenia Res. 7:1992;77-84.
30. O'Keane V., O'Hanlon M., Webb M., Dinan T.G. D-Fenfluramine/prolactin response throughout the menstrual cycle Evidence for an oestrogen-induced alteration . Clin Endocrinol. 34:1991;289-292.
31. Ranjan R., Lee M.A., Meltzer H.Y. Effect of MK-212, a centrally acting serotonin agonist, on prolactin, cortisol and body temperature in schizophrenia. Biol Psychiatry. 37:1995;678-679.
32. Tuomisto J., Mannisto P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev. 73:1985;249-332.
33. Composite International Diagnostic Interview. 1987;WHO, Geneva.
34. Yatham L.M., Steiner M. Neuroendocrine probes of serotonergic function A critical review . Life Sci. 53:1993;447-463.